In the last trading session, 2.02 million Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) shares changed hands as the company’s beta touched 0.34. With the company’s per share price at $1.80 changed hands at -$0.02 or -0.83% during last session, the market valuation stood at $288.05M. IRWD’s last price was a discount, traded about -747.78% off its 52-week high of $15.26. The share price had its 52-week low at $1.59, which suggests the last value was 11.67% up since then.
Analysts gave the Ironwood Pharmaceuticals Inc (IRWD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.33. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IRWD as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Ironwood Pharmaceuticals Inc’s EPS for the current quarter is expected to be 0.08.
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) trade information
Instantly IRWD was in red as seen at the end of in last trading. With action -6.25%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -59.37%, with the 5-day performance at -6.25% in the red. However, in the 30-day time frame, Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) is -52.25% down.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 70.0% from its current market value. According to analyst projections, IRWD’s forecast low is 5 with 7 as the target high. To hit the forecast high, the stock’s price needs a -288.89% plunge from its current level, while the stock would need to soar -177.78% for it to hit the projected low.
Ironwood Pharmaceuticals Inc (IRWD) estimates and forecasts
Year-over-year growth is forecast to reach -19.90% down from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 93.85M. 5 analysts are of the opinion that Ironwood Pharmaceuticals Inc’s revenue for the current quarter will be 67.36M. The company’s revenue for the corresponding quarters a year ago was 117.55M and 74.88M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -20.16%. The estimates for the next quarter sales put growth at -10.04%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -28.37%. The 2025 estimates are for Ironwood Pharmaceuticals Inc earnings to increase by 101.20%.
IRWD Dividends
Ironwood Pharmaceuticals Inc is expected to release its next quarterly earnings report in March.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 13.6737% or 21.56 million shares worth $140.59 million as of 2024-06-30.
Among Mutual Funds, the top two as of Oct 31, 2024 were Pacer Small Cap U.S. Cash Cows 100 ETF and iShares Core S&P Smallcap ETF . With 11.05 shares estimated at $19.89 million under it, the former controlled 6.90% of total outstanding shares. On the other hand, iShares Core S&P Smallcap ETF held about 5.70% of the shares, roughly 9.12 shares worth around $16.42 million.
